{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:23:03Z","timestamp":1776172983991,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer (NSCLC) who had previously received bevacizumab.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The participants were histopathologically or cytologically diagnosed advanced NSCLC patients whose disease progressed after at least one type of systemic therapy and who had previously received bevacizumab treatment. The patients were on 3-week administration cycles, including 2\u00a0weeks on-treatment (12\u00a0mg anlotinib oral route, once a day) and 1\u00a0week off-treatment. The primary end point of the trial was overall survival (OS). The secondary end points were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> As of the data collection deadline (31 March 2021), 30 patients were enrolled in the study and received anlotinib treatment. All patients were included in the data set except one, who withdrew their consent after the start of treatment. The median follow-up period was 12.1\u00a0months (range, 3.6\u201325.0\u00a0months), and 29 patients were included in the evaluation of the treatment. Of the 29 patients, no CR cases occurred. In total, three patients (10.2%) showed a PR, 21 (72.4%) had SD, and five patients (17.2%) had PD. The objective response rate (ORR) was 10.2% (3 of 29 patients), and the disease control rate (DCR) was 82.7% (24 of 29 patients). The median progression-free survival (PFS) was 5.6\u00a0months (95% CI, 5.0\u20136.1\u00a0months; <jats:xref>Figure 2<\/jats:xref>). The median overall survival (OS) was 10.6\u00a0months (95% CI, 9.4\u201311.8\u00a0months; <jats:xref>Figure 3<\/jats:xref>). The overall tolerance of the anlotinib treatment was high among the enrolled patients. No treatment-related grade four or five toxicities were observed. Of the 29 patients, one patient\u2019s anlotinib administration was reduced to 8\u00a0mg\/day due to hypertension and headache. Most adverse events (AEs) were grade one or two; the most common AEs were fatigue (51.7%), hypertension (41.3%), hand\u2013foot syndrome (41.4%), anorexia (34.5%) and hypertriglyceridemia (34.5%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Anlotinib demonstrated favourable activity and manageable toxicity in NSCLC patients who were treated with bevacizumab previously.<\/jats:p>","DOI":"10.3389\/fphar.2022.973448","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T13:41:26Z","timestamp":1664286086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab"],"prefix":"10.3389","volume":"13","author":[{"given":"Fenge","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangshuo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-6-31","article-title":"Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition","volume":"6","author":"Falcon","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: New concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann. Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","article-title":"Anlotinib as a molecular targeted therapy for tumors","volume":"20","author":"Gao","year":"2020","journal-title":"Oncol. Lett."},{"key":"B8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2165\/11317600-000000000-00000","article-title":"Monoclonal antibodies targeting vascular endothelial growth factor: Current status and future challenges in cancer therapy","volume":"23","author":"Hsu","year":"2009","journal-title":"BioDrugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1634\/theoncologist.2019-0838","article-title":"The impact of anlotinib on brain metastases of non-small cell lung cancer: Post hoc analysis of a phase III randomized control trial (ALTER0303)","volume":"25","author":"Jiang","year":"2020","journal-title":"Oncologist"},{"key":"B11","first-page":"167","article-title":"Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update","volume":"27","author":"Jonna","year":"2019","journal-title":"Discov. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer","volume":"31","author":"Patel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00432-020-03129-6","article-title":"New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer","volume":"146","author":"Qiang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00432-020-03129-6","article-title":"New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer","volume":"146","author":"Qiang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17476348.2020.1701439","article-title":"Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations","volume":"14","author":"Reck","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"a009092","DOI":"10.1101\/cshperspect.a009092","article-title":"VEGFR and type-V RTK activation and signaling","volume":"5","author":"Shibuya","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"Ca. Cancer J. Clin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"Ca. Cancer J. Clin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"788837","DOI":"10.3389\/fonc.2021.788837","article-title":"A retrospective analysis of the effect of anlotinib in patients with lung cancer with or without previous antiangiogenic therapy","volume":"11","author":"Suo","year":"2021","journal-title":"Front. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3390\/cells9112467","article-title":"Notch signaling function in the angiocrine regulation of tumor development","volume":"9","author":"Trindade","year":"2020","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.21037\/tlcr.2019.09.21","article-title":"The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): A subgroup analysis of ALTER0303 trial","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Lung Cancer Res."}],"updated-by":[{"DOI":"10.3389\/fphar.2022.1092147","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T16:39:58Z","timestamp":1669135198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":23,"alternative-id":["10.3389\/fphar.2022.973448"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.973448","relation":{"erratum":[{"id-type":"doi","id":"10.3389\/fphar.2022.1092147","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"973448"}}